Applying a risk assessment guided evaluation for verifying comprehensive two-dimensional gas chromatography to analyse complex pharmaceuticals
The reliability of analytical results is critical and indispensable when applied in regulated environments such as the pharmaceutical industry. Therefore, analytical workflows must be validated. However, validation guidelines are often designed for quantitative targeted analysis and rarely apply to qualitative untargeted approaches. In this study, we employ a risk assessment approach to identify critical parameters which might influence the qualitative results derived by online derivatisation — comprehensive two-dimensional gas chromatography coupled to a high-resolution time-of-flight mass spectrometer (GC × GC-HR-ToF–MS) for the analysis of the active pharmaceutical ingredient (API) sodium bituminosulfonate (SBS). To show the complexity and feasibility of such an approach, we focus on investigating three potential risk factors: sample preparation, vapourability, and the thermal stability of sulfonates. Through the individual evaluation of these potential risk factors due to the application of sample preparation approaches and thermal gravimetric analysis (TGA), we demonstrate the high derivatisation efficiency and repeatability of the online derivatisation method and confirm the absence of derivatisation-induced side reactions. In addition, we also show the potential thermal instability of an incompletely derivatised API. To address the limitation of these individual assessments, we applied a holistic evaluation step with negative electrospray ionisation Fourier transform ion cyclotron resonance mass spectrometry (ESI( −) FT-ICR MS) as an orthogonal technique. This confirms that most of the API is detected via the presented GC-based method. Thereby, we demonstrated the practical feasibility of the risk assessment-based approach to ensure the validity of the qualitative data for a complex untargeted method. Graphical Abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:416 |
|---|---|
| Enthalten in: |
Analytical and bioanalytical chemistry - 416(2023), 4 vom: 21. Dez., Seite 1033-1045 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schwalb, Lukas [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
FT-ICR MS |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s00216-023-05093-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054466148 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054466148 | ||
| 003 | DE-627 | ||
| 005 | 20240122064601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00216-023-05093-9 |2 doi | |
| 035 | |a (DE-627)SPR054466148 | ||
| 035 | |a (SPR)s00216-023-05093-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schwalb, Lukas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Applying a risk assessment guided evaluation for verifying comprehensive two-dimensional gas chromatography to analyse complex pharmaceuticals |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a The reliability of analytical results is critical and indispensable when applied in regulated environments such as the pharmaceutical industry. Therefore, analytical workflows must be validated. However, validation guidelines are often designed for quantitative targeted analysis and rarely apply to qualitative untargeted approaches. In this study, we employ a risk assessment approach to identify critical parameters which might influence the qualitative results derived by online derivatisation — comprehensive two-dimensional gas chromatography coupled to a high-resolution time-of-flight mass spectrometer (GC × GC-HR-ToF–MS) for the analysis of the active pharmaceutical ingredient (API) sodium bituminosulfonate (SBS). To show the complexity and feasibility of such an approach, we focus on investigating three potential risk factors: sample preparation, vapourability, and the thermal stability of sulfonates. Through the individual evaluation of these potential risk factors due to the application of sample preparation approaches and thermal gravimetric analysis (TGA), we demonstrate the high derivatisation efficiency and repeatability of the online derivatisation method and confirm the absence of derivatisation-induced side reactions. In addition, we also show the potential thermal instability of an incompletely derivatised API. To address the limitation of these individual assessments, we applied a holistic evaluation step with negative electrospray ionisation Fourier transform ion cyclotron resonance mass spectrometry (ESI( −) FT-ICR MS) as an orthogonal technique. This confirms that most of the API is detected via the presented GC-based method. Thereby, we demonstrated the practical feasibility of the risk assessment-based approach to ensure the validity of the qualitative data for a complex untargeted method. Graphical Abstract | ||
| 650 | 4 | |a GC × GC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a HR-MS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Risk assessment |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-biological complex drugs |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sodium bituminosulfonate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a FT-ICR MS |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Tiemann, Ole |4 aut | |
| 700 | 1 | |a Käfer, Uwe |4 aut | |
| 700 | 1 | |a Rüger, Christopher Paul |4 aut | |
| 700 | 1 | |a Gröger, Thomas |4 aut | |
| 700 | 1 | |a Zimmermann, Ralf |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Analytical and bioanalytical chemistry |d Berlin : Springer, 2002 |g 416(2023), 4 vom: 21. Dez., Seite 1033-1045 |w (DE-627)SPR002080982 |w (DE-600)1459122-4 |x 1618-2650 |7 nnns |
| 773 | 1 | 8 | |g volume:416 |g year:2023 |g number:4 |g day:21 |g month:12 |g pages:1033-1045 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00216-023-05093-9 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 416 |j 2023 |e 4 |b 21 |c 12 |h 1033-1045 | ||